☰

Kunal Kumar - Publications

Affiliations: 
Pharmacology Icahn School of Medicine at Mount Sinai, New York, NY, United States 
Tree Info Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Wang P, Karakose E, Choleva L, Kumar K, DeVita RJ, Garcia-Ocaña A, Stewart AF. Human Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges. Frontiers in Endocrinology. 12: 671946. PMID 34335466 DOI: 10.3389/fendo.2021.671946  0.637
2021 Sebastian-Valverde M, Wu H, Al Rahim M, Sanchez R, Kumar K, De Vita RJ, Pasinetti GM. Discovery and characterization of small molecule inhibitors of NLRP3 and NLRC4 inflammasomes. The Journal of Biological Chemistry. 100597. PMID 33781745 DOI: 10.1016/j.jbc.2021.100597  0.381
2021 Kumar K, Suebsuwong C, Wang P, Garcia-Ocana A, Stewart AF, DeVita RJ. DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes. Journal of Medicinal Chemistry. PMID 33682417 DOI: 10.1021/acs.jmedchem.0c02050  0.657
2020 Kumar K, Wang P, A Swartz E, Khamrui S, Secor C, B Lazarus M, Sanchez R, F Stewart A, DeVita RJ. Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation. Molecules (Basel, Switzerland). 25. PMID 32340326 DOI: 10.3390/Molecules25081983  0.737
2020 Ackeifi C, Wang P, Karakose E, Manning Fox JE, González BJ, Liu H, Wilson J, Swartz E, Berrouet C, Li Y, Kumar K, MacDonald PE, Sanchez R, Thorens B, DeVita R, et al. GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human β cell regeneration. Science Translational Medicine. 12. PMID 32051230 DOI: 10.1126/Scitranslmed.Aaw9996  0.729
2020 Kumar K, Wang P, Wilson J, Zlatanic V, Berrouet C, Khamrui S, Secor C, Swartz E, Lazarus MB, Sanchez R, Stewart AF, Garcia-Ocana A, DeVita RJ. Synthesis and Biological Validation of a Harmine-based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor. Journal of Medicinal Chemistry. PMID 32003560 DOI: 10.1021/Acs.Jmedchem.9B01379  0.736
2019 Ackeifi C, Swartz E, Kumar K, Liu H, Chalada S, Karakose E, Scott DK, Garcia-Ocaña A, Sanchez R, DeVita RJ, Stewart AF, Wang P. Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors. Jci Insight. PMID 31821176 DOI: 10.1172/Jci.Insight.132594  0.653
2018 Kumar K, Man-Un Ung P, Wang P, Wang H, Li H, Andrews MK, Stewart AF, Schlessinger A, DeVita RJ. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity. European Journal of Medicinal Chemistry. 157: 1005-1016. PMID 30170319 DOI: 10.1016/J.Ejmech.2018.08.007  0.732
2018 Kumar K, Wang P, Sanchez R, Swartz E, Stewart AF, DeVita RJ. Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation. Journal of Medicinal Chemistry. PMID 30059217 DOI: 10.1021/Acs.Jmedchem.8B00658  0.751
2017 Alford VM, Kamath A, Ren X, Kumar K, Gan Q, Awwa M, Tong M, Seeliger MA, Cao J, Ojima I, Sampson NS. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. Acs Chemical Biology. PMID 28945333 DOI: 10.1021/Acschembio.7B00758  0.373
2015 Teng YH, Berger WT, Nesbitt NM, Kumar K, Balius TE, Rizzo RC, Tonge PJ, Ojima I, Swaminathan S. Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A. Bioorganic & Medicinal Chemistry. 23: 5489-95. PMID 26275678 DOI: 10.1016/J.Bmc.2015.07.040  0.383
2015 Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. The Journal of Antimicrobial Chemotherapy. PMID 26245639 DOI: 10.1093/Jac/Dkv226  0.367
2014 Knudson SE, Kumar K, Awasthi D, Ojima I, Slayden RA. In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 94: 271-6. PMID 24746463 DOI: 10.1016/J.Tube.2014.03.007  0.4
2014 Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. Plos One. 9: e93953. PMID 24736743 DOI: 10.1371/Journal.Pone.0093953  0.365
2014 Park B, Awasthi D, Chowdhury SR, Melief EH, Kumar K, Knudson SE, Slayden RA, Ojima I. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents. Bioorganic & Medicinal Chemistry. 22: 2602-12. PMID 24726304 DOI: 10.1016/J.Bmc.2014.03.035  0.399
2014 Ojima I, Kumar K, Awasthi D, Vineberg JG. Drug discovery targeting cell division proteins, microtubules and FtsZ. Bioorganic & Medicinal Chemistry. 22: 5060-77. PMID 24680057 DOI: 10.1016/J.Bmc.2014.02.036  0.378
2013 Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I. SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. Journal of Medicinal Chemistry. 56: 9756-70. PMID 24266862 DOI: 10.1021/Jm401468W  0.427
2013 Kumar K, Awasthi D, Lee SY, Cummings JE, Knudson SE, Slayden RA, Ojima I. Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorganic & Medicinal Chemistry. 21: 3318-26. PMID 23623254 DOI: 10.1016/J.Bmc.2013.02.059  0.312
2011 Awasthi D, Kumar K, Ojima I. Therapeutic potential of FtsZ inhibition: a patent perspective. Expert Opinion On Therapeutic Patents. 21: 657-79. PMID 21413908 DOI: 10.1517/13543776.2011.568483  0.369
2011 Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. Journal of Medicinal Chemistry. 54: 374-81. PMID 21126020 DOI: 10.1021/Jm1012006  0.411
2010 Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Medicinal Chemistry. 2: 1305-23. PMID 21339840 DOI: 10.4155/Fmc.10.220  0.364
Show low-probability matches.